Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Less than a day after the US Food and Drug Administration granted emergency use authorization to Abbott for its rapid COVID-19 antigen test, the federal government has agreed to buy 150 million of them.
Abbott’s $5 point-of-care BinaxNOW COVID-19 Ag Card detects SARS-CoV-2, the virus that causes COVID-19. It’s intended for people suspected of having the virus within the first seven days of symptom onset. (See sidebar story.)
The company will be paid $760m for the tests under a contract with the Department of Health and Human Services (HHS) and the Department of Defense.
BinaxNOW uses lateral flow technology to test nasal-swab samples on a device the size of a credit card and produces a result in roughly 15 minutes, Abbott says. The test doesn’t require any other equipment to process samples or read results, and uses only a “minimal” amount of chemical reagents.
The HHS says the tests “will be potentially deployed to schools and to assist with serving other special needs populations.”
“By strategically distributing 150 million of these tests to where they’re needed most, we can track the virus like never before and protect millions of Americans at risk in especially vulnerable situations,” HHS secretary Alex Azar said in a 27 August statement.
Abbott says it has invested “hundreds of millions of dollars” since April in two new US facilities to manufacture BinaxNOW. The company plans to ramp up production to 50 million tests a month by the beginning of October.
Medtech Insight: global medical technology news & analysis
16 Apr 2021
The pandemic has exacerbated the problems of the Turkish medical device industry, which was already struggling for survival and growth...
Medtech Insight: global medical technology news & analysis
16 Apr 2021
Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current...
Medtech Insight: global medical technology news & analysis
16 Apr 2021
Medical robotics company Vicarious Surgical announced it will merge with blank check company D8 Holdings Corp. in a deal that...
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Looking for more products Product Finder
